Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.18EUR
8 Dec 2017
Change (% chg)

€-0.03 (-0.04%)
Prev Close
€73.21
Open
€73.50
Day's High
€74.10
Day's Low
€72.92
Volume
2,324,309
Avg. Vol
2,039,521
52-wk High
€92.97
52-wk Low
€72.63

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €92,436.16
Shares Outstanding(Mil.): 1,263.13
Dividend: 2.96
Yield (%): 4.04

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Sanofi Explores Combination Treatments For Multiple Myeloma In New Late-Stage Trials

* SANOFI EXPLORES COMBINATION TREATMENTS FOR MULTIPLE MYELOMA IN NEW LATE-STAGE TRIALS

Dec 07 2017

Trouble mounts for Sanofi dengue vaccine over safety concerns

The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases.

Dec 05 2017

France advised against Sanofi's dengue drug for its territories

PARIS A public body close to France's health ministry last year advised against the use of a dengue vaccine in the country's overseas territories that is currently at the center of a health scare, regulatory documents show.

Dec 05 2017

Philippines halts sale of dengue vaccine as Sanofi downplays risk

MANILA/LONDON The Philippines has ordered French drugmaker Sanofi to stop the sale, distribution and marketing of its Dengvaxia dengue vaccine in the country after the company last week warned it could worsen the disease in some cases. | Video

Dec 05 2017

UPDATE 2-Philippines halts sale of dengue vaccine as Sanofi downplays risk

MANILA/LONDON, Dec 5 The Philippines has ordered French drugmaker Sanofi to stop the sale, distribution and marketing of its Dengvaxia dengue vaccine in the country after the company last week warned it could worsen the disease in some cases.

Dec 05 2017

Severe dengue vaccine risk in uninfected '2 in a 1,000': Sanofi

LONDON French drugmaker Sanofi said on Tuesday the risk of severe dengue occurring in previously uninfected people given its Dengvaxia dengue vaccine was around two in 1,000 and these individuals recovered with treatment.

Dec 05 2017

Philippines halts sale of Sanofi dengue vaccine amid health risk

MANILA, Dec 5 The Philippines has ordered French drugmaker Sanofi to stop the sale, distribution and marketing of its Dengvaxia dengue vaccine in the country after the company last week warned it could worsen the disease in some cases.

Dec 04 2017

Philippines orders probe into Sanofi dengue vaccine for 730,000 children

MANILA The Philippines ordered an investigation on Monday into the immunization of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by French drug company Sanofi that it could worsen the disease in some cases.

Dec 04 2017

BRIEF-EMA says Sanofi's dengue vaccine currently being reviewed, to take new data into account

* European Medicines Agency says in emailed statement Sanofi's dengue vaccine is currently being reviewed for a central marketing authorisation by the Agency's Committee for Medicinal Products for Human Use (CHMP)

Dec 04 2017

Brazil recommends restrictions on Sanofi dengue vaccine

BRASILIA The Brazilian government said on Monday it has suggested restrictions on the use of a dengue vaccine that has been suspended elsewhere after French drug company Sanofi SA said it could worsen the disease in some cases.

Dec 04 2017

Earnings vs. Estimates